Evidence map›Paper›PMID 39763682›Full record

Trial reportFrontiers in immunology2024

Tacrolimus to belatacept conversion in proteinuric kidney transplant recipients.

Orhan Efe, Ayman Al Jurdi, Morgan Mabey Eiting, Christine Rogers Marks, Mariesa Ann Cote, David Wojciechowski, Kassem Safa, Hannah Gilligan, Jamil Azzi, Nitender Goyal and 4 more

Abstract readMulticenter StudyClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Orhan EfeDivision of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA, United States.
Ayman Al JurdiDivision of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA, United States.
Morgan Mabey EitingSolid Organ Transplant Pharmacy, Massachusetts General Hospital, Boston, MA, United States.
Christine Rogers MarksSolid Organ Transplant Pharmacy, Massachusetts General Hospital, Boston, MA, United States.
Mariesa Ann CoteSolid Organ Transplant Pharmacy, Massachusetts General Hospital, Boston, MA, United States.
David WojciechowskiKidney Transplantation Program, UT Southwestern Medical Center, Dallas, TX, United States.
Kassem SafaDivision of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA, United States.
Hannah GilliganDivision of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA, United States.
Jamil AzziTransplantation Research Center, Renal Division, Brigham and Women's Hospital, Boston, MA, United States.
Nitender GoyalDivision of Nephrology, Tufts Medical Center, Boston, MA, United States.
Marc RaynaudParis Translational Research Center for Organ Transplantation, INSERM, Paris Cardiovascular Research Center, Université de Paris, Paris, France.
Alexandre LoupyParis Translational Research Center for Organ Transplantation, INSERM, Paris Cardiovascular Research Center, Université de Paris, Paris, France.
Astrid WeinsDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, United States.
Leonardo V RiellaDivision of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Proteinuria is associated with worse allograft outcomes in kidney transplant recipients (KTRs) and treatment strategies are limited. We examined the outcomes of calcineurin inhibitor (CNI) to belatacept conversion in proteinuric KTRs. Methods: In a pilot phase II single-arm multicenter prospective trial, we recruited adult KTRs >6 months post-kidney transplantation with an estimated glomerular filtration rate (eGFR) ≥30 ml/min/1.73m Results: A total of 15 KTRs were recruited who had pre-conversion median (interquartile range) proteinuria of 1.8 (IQR 1.4 - 3.5) g/g and estimated glomerular filtration rate (eGFR) of 48 (IQR 32 - 52.5) ml/min/1.73m Conclusions: CNI to belatacept conversion was associated with preserved allograft function in KTRs with significant proteinuria. These findings need to be confirmed in a larger randomized clinical trial. Clinical trial registration: https://clinicaltrials.gov/,

Indexed as

AbataceptGlomerular Filtration RateImmunosuppressive AgentsKidney TransplantationProteinuriaTacrolimusAdultAgedCalcineurin InhibitorsFemaleGraft RejectionGraft SurvivalHumansMaleMiddle AgedPilot ProjectsAbataceptCalcineurin InhibitorsImmunosuppressive AgentsTacrolimusbelatacept conversiongraft functionkidney transplantationproteinuriaproteinuria reduction

Identifiers

PMID39763682
PMCPMC11701005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.